Human Japanese Encephalitis Virus antibodies and methods of use therefor
AssigneeVanderbilt University
InventorJames E. Crowe, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.
Claims20
A method of detecting a Japanese Encephalitis virus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antigen-binding fragment thereof having heavy and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 17-19 and 29-31, SEQ ID NOS:
- 26-28 and 38-40, SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS:
- 23-25 and 35-37, respectively;
- and
- (b) detecting Japanese Encephalitis virus in said sample by binding of said antibody or antibody fragment to a Japanese Encephalitis virus antigen in said sample.
A method of treating a subject infected with Japanese Encephalitis virus comprising delivering to said subject an effective amount an antibody or antigen-binding fragment thereof having heavy and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS:
- 23-25 and 35-37, respectively.
An isolated monoclonal antibody or antigen-binding fragment thereof, comprising heavy and light chain CDR sequences comprising SEQ ID NOS:
- 17-19 and 29-31, SEQ ID NOS:
- 26-28 and 38-40, SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS 23-25 and 35-37, respectively.
A hybridoma or engineered cell encoding an antibody or antigen-binding fragment thereof, comprising heavy and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 17-19 and 29-31, SEQ ID NOS:
- 26-28 and 38-40, SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS:
- 23-25 and 35-37, respectively.
A vaccine formulation comprising one or more antibodies or antigen-binding fragments thereof, comprising heavy and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS:
- 23-25 and 35-37, respectively.
A method of determining stability over time of an antigen comprising:
- (a) contacting a sample comprising said antigen with a first antibody or antigen-binding fragment thereof having heavy and light chain CDR1-3 sequences comprising SEQ ID NOS:
- 17-19 and 29-31, SEQ ID NOS:
- 26-28 and 38-40, SEQ ID NOS:
- 20-22 and 32-34 or SEQ ID NOS:
- 23-25 and 35-37, respectively;
- and
- (b) determining stability over time of said antigen by detectable binding of said antibody or antigen-binding fragment thereof to said antigen.
Dependencies are inferred from the claim text.